4-FA

4-Fluoroamphetamine (4-FA) is a fluorinated analog of amphetamine in which a fluorine atom occupies the 4-position (para) of the phenyl ring. It is classified simultaneously as an Entactogen and Stimulant, reflecting a dose-dependent dual pharmacological profile: at lower doses (50–100 mg) it produces primarily stimulant effects comparable to amphetamine, while at higher doses (100–200 mg) a significant entactogenic component emerges, producing empathy, emotional warmth, and mild MDMA-like sociability. This MDMA-adjacent profile at typical doses made 4-FA uniquely popular in the Netherlands, where it was used widely as a "safer MDMA alternative" — particularly after it remained unscheduled while MDMA remained illegal.

The para-fluorine substitution at the 4-position dramatically increases 4-FA's serotonin releasing activity compared to 2-FA or 3-FA, producing an effect profile distinct from any other common fluorinated amphetamine. Community experience consistently describes the full-dose 4-FA experience as a cleaner, longer, and less physically taxing entactogen than MDMA, with more prominent stimulant character and a reportedly milder comedown. Duration is typically 5–7 hours — longer than MDMA but shorter than 2-FMA or 3-FPM.

The widespread use of 4-FA in the Netherlands came to an abrupt end following a series of serious adverse events — including cases of hypertensive crisis and at least several deaths — linked to 4-FA use in 2017–2018, leading to emergency scheduling. These events established that despite its reputation as "gentler" than MDMA, 4-FA carries significant cardiovascular and neurotoxic risks, particularly at higher doses and with mixed use with alcohol or other substances. Reagent testing is important as 4-FA is sometimes misrepresented as MDMA.